$1.17
1.68%
Nasdaq, Sep 25, 04:01 pm EDT. Closed.

MaxCyte Inc Target price 2026 - Analyst rating & recommendation

MaxCyte Inc Classifications & Recommendation

Buy
83%
Hold
17%

MaxCyte Inc Price Target

Target Price $4.59
Price $1.17
Potential
Number of Estimates 6
6 Analysts have issued a price target MaxCyte Inc 2027 . The average MaxCyte Inc target price is $4.59. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 12 analysts: 10 Analysts recommend MaxCyte Inc to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the MaxCyte Inc stock has an average upside potential 2027 of . Most analysts recommend the MaxCyte Inc stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Revenue Million $ 33.03 32.01
14.50% 3.10%
EBITDA Margin -122.04% -83.50%
0.20% 31.58%
Net Margin -135.12% -94.16%
27.12% 30.31%

8 Analysts have issued a sales forecast MaxCyte Inc 2026 . The average MaxCyte Inc sales estimate is

$32.0m
unlock
. This is
3.08% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$33.6m 8.14%
unlock
, the lowest is
$29.9m 3.74%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 $33.0m 14.50%
2026
$32.0m 3.10%
unlock
2027
$37.8m 18.24%
unlock
2028
$44.7m 18.04%
unlock
2029
$66.5m 48.93%
unlock
2030
$93.1m 40.00%
unlock
2031
$140m 50.00%
unlock
2032
$210m 50.00%
unlock
2033
$304m 45.00%
unlock

7 Analysts have issued an MaxCyte Inc EBITDA forecast 2026. The average MaxCyte Inc EBITDA estimate is

$-26.7m
unlock
. This is
29.18% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-24.1m 36.25%
unlock
, the lowest is
$-29.0m 23.14%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 $-40.3m 14.33%
2026
$-26.7m 33.70%
unlock
2027
$-20.7m 22.41%
unlock
2028
$-19.3m 7.03%
unlock
2029
$-9.9m 48.68%
unlock
2030
$4.9m 149.48%
unlock

EBITDA Margin

2025 -122.04% 0.20%
2026
-83.50% 31.58%
unlock
2027
-54.80% 34.37%
unlock
2028
-43.16% 21.24%
unlock

8 MaxCyte Inc Analysts have issued a net profit forecast 2026. The average MaxCyte Inc net profit estimate is

$-30.1m
unlock
. This is
15.43% higher
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-27.9m 21.83%
unlock
, the lowest is
$-31.2m 12.46%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 $-44.6m 8.69%
2026
$-30.1m 32.47%
unlock
2027
$-27.2m 9.79%
unlock
2028
$-25.6m 6.03%
unlock

Net Margin

2025 -135.12% 27.12%
2026
-94.16% 30.31%
unlock
2027
-71.86% 23.68%
unlock
2028
-57.19% 20.41%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Earnings Per Share $ -0.42 -0.28
7.69% 33.33%
P/E negative
EV/Sales 0.54

8 Analysts have issued a MaxCyte Inc forecast for earnings per share. The average MaxCyte Inc EPS is

$-0.28
unlock
. This is
15.15% higher
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$-0.26 21.21%
unlock
, the lowest is
$-0.29 12.12%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $-0.42 7.69%
2026
$-0.28 33.33%
unlock
2027
$-0.26 7.14%
unlock
2028
$-0.24 7.69%
unlock
2029
$-0.11 54.17%
unlock
2030
$0.00 100.00%
unlock

P/E ratio

Current -3.61 0.36%
2026
-4.19 16.19%
unlock
2027
-4.64 10.74%
unlock
2028
-4.94 6.47%
unlock

Based on analysts' sales estimates for 2026, the MaxCyte Inc stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 0.55 44.44%
2026
0.54 2.69%
unlock
2027
0.45 15.41%
unlock
2028
0.38 15.29%
unlock
2029
0.26 32.86%
unlock
2030
0.18 28.58%
unlock
2031
0.12 33.33%
unlock
2032
0.08 33.36%
unlock
2033
0.06 30.97%
unlock

P/S ratio

Current 3.96 12.73%
2026
3.84 2.98%
unlock
2027
3.25 15.42%
unlock
2028
2.75 15.28%
unlock
2029
1.85 32.86%
unlock
2030
1.32 28.57%
unlock
2031
0.88 33.34%
unlock
2032
0.59 33.33%
unlock
2033
0.40 31.04%
unlock

Current MaxCyte Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Craig-Hallum
Locked
➜
Locked
Locked Mar 25 2026
BTIG
Locked
➜
Locked
Locked Aug 11 2025
William Blair
Locked
➜
Locked
Locked Aug 07 2025
Stifel
Locked
➜
Locked
Locked Mar 12 2025
Analyst Rating Date
Locked
Craig-Hallum:
Locked
➜
Locked
Mar 25 2026
Locked
BTIG:
Locked
➜
Locked
Aug 11 2025
Locked
William Blair:
Locked
➜
Locked
Aug 07 2025
Locked
Stifel:
Locked
➜
Locked
Mar 12 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today